What's Happening?
Precision BioSciences, a clinical stage gene editing company, is set to present new clinical biopsy data from its ongoing Phase 1 ELIMINATE-B trial at the European Association for the Study of the Liver (EASL) Congress 2026. The trial is evaluating PBGENE-HBV,
a gene editing therapy designed to treat chronic hepatitis B by eliminating the root cause of the infection, cccDNA, and inactivating integrated HBV DNA. This therapy is the first of its kind to enter clinical trials with the potential to cure chronic hepatitis B. The presentation will highlight the elimination and inactivation of cccDNA in liver biopsies from patients treated with PBGENE-HBV. The EASL Congress will take place from May 27-30, 2026, in Barcelona, Spain.
Why It's Important?
The development of PBGENE-HBV represents a significant advancement in the treatment of chronic hepatitis B, a condition that affects millions worldwide and currently lacks a definitive cure. By targeting cccDNA, the therapy aims to eliminate the source of infectious replication, potentially leading to a cure. This could transform the treatment landscape for hepatitis B, offering hope to patients who have limited options. The therapy's progress also underscores the potential of gene editing technologies in addressing complex viral infections, highlighting Precision BioSciences' innovative approach using its ARCUS platform. The FDA's Fast Track designation for PBGENE-HBV further emphasizes its potential impact and the urgency of developing effective treatments for chronic hepatitis B.
What's Next?
Following the presentation at the EASL Congress, Precision BioSciences will likely continue to advance the clinical development of PBGENE-HBV, with further trials to confirm its efficacy and safety. The company may also seek additional regulatory approvals and partnerships to support the therapy's commercialization. Stakeholders, including healthcare providers and patients, will be closely monitoring the trial outcomes, as successful results could lead to a new standard of care for chronic hepatitis B. Additionally, the broader gene editing field will be watching for insights into the application of ARCUS technology in treating other genetic and infectious diseases.
